MIRM – mirum pharmaceuticals, inc. - common stock (US:NASDAQ)

DELAYED
$ usd
Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low
VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close
1D
5D
1M
3M
YTD
1Y
3Y
1 Day MIRM SPY QQQ SPX
Date
Time
Symbol
Company Name
Action
%Chg
11/4/2025
04:01 pm
mirm
mirum pharmaceuticals, inc. - common stock
BEAT
-1.2%
8/6/2025
04:01 pm
mirm
mirum pharmaceuticals, inc. - common stock
BEAT
12.0%
5/7/2025
04:01 pm
mirm
mirum pharmaceuticals, inc. - common stock
BEAT
9.8%
Earnings are essential to understanding the financial health of a company listed on any Stock Exchange. But what are Earnings, how are they calculated, when are they announced, and how are they used to make sound investment decisions?
The answers are right here.
Stock Stats
News Stats
All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings
Order Stats
Sub-Penny
Odd Lot
Avg. bid-ask spread
Avg. bid / ask size
Shares at ask / bid
Off exchange
Top News Gainers
12/13 Mirum Pharmaceuticals to Provide Regulatory Update in Upcoming Conference Call and Webcast 111.0%
3/23 Form 4 Mirum Pharmaceuticals, For: Mar 19 Filed by: Tucker Edwin Jonathan 20.8%
3/12 Form 10-K Mirum Pharmaceuticals, For: Dec 31 16.2%
1/16 Frazier Healthcare Partners Closes Oversubscribed $617 Million Life Sciences Fund 15.2%
12/7 Mirum Pharmaceuticals (NASDAQ: MIRM) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 11.2%
4/17 Mirum Pharmaceuticals (NASDAQ: MIRM) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 6.0%
4/28 Mirum Pharmaceuticals Appoints Peter Radovich as Chief Operating Officer 5.5%
4/30 Form 3 Mirum Pharmaceuticals, For: Apr 28 Filed by: Radovich Peter 5.4%
2/18 Mirum Pharmaceuticals to Participate at Four Upcoming Conferences 5.0%
4/9 Mirum Pharmaceuticals (NASDAQ: MIRM) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $15.00 price target on the stock. 4.7%
Top News Decliners
3/17 Mirum Pharmaceuticals (MIRM) Investor Presentation - Slideshow [Seeking Alpha] -10.7%
1/8 Mirum Pharmaceuticals Announces Pricing of Public Offering -6.6%
1/6 Form S-1 Mirum Pharmaceuticals, -6.0%
12/17 Mirum Pharmaceuticals (NASDAQ: MIRM) had its price target raised by analysts at Citigroup Inc from $21.00 to $30.00. They now have a "buy" rating on the stock. -5.8%
4/16 Mirum Pharmaceuticals (NASDAQ: MIRM) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $17.00 price target on the stock. -5.6%
1/9 Form 424B4 Mirum Pharmaceuticals, -5.0%
8/28 Mirum Pharmaceuticals Reports Second Quarter Financial Results and Provides Corporate Update -4.8%
8/12 Mirum Pharmaceuticals (NASDAQ: MIRM) is now covered by analysts at Citigroup Inc. They set a "buy" rating on the stock. -4.6%
12/28 Mirum Pharmaceuticals (NASDAQ: MIRM) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -4.4%
9/26 Mirum Pharmaceuticals to Present at Cantor 2019 Global Healthcare Conference -3.9%

Don’t Miss Out On The Next BIG Stock Move

Thanks for submitting the form.
MIRM – mirum pharmaceuticals, inc. - common stock (US:NASDAQ)
DELAYED
$ usd
1D
5D
1M
3M
YTD
1Y
3Y
Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low
VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close
MIRM
SPY
QQQ
SPX
MIRM – mirum pharmaceuticals, inc. - common stock (US:NASDAQ)
DELAYED
$ usd
1D
5D
1M
3M
YTD
1Y
3Y
Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low
VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close
MIRM SPY QQQ SPX
Stock Stats
All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings
Sub-Penny
Odd Lot
Avg. bid-ask spread
Avg. bid / ask size
Shares at ask / bid
Off exchange
Stock Stats
Order Stats
Sub-Penny
Odd Lot
Avg. bid-ask spread
Avg. bid / ask size
Shares at ask / bid
Off exchange
News Stats
All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings
News
12/11
09:04 am
mirm
Low
Mirum Pharmaceuticals (NASDAQ:MIRM) had its "strong-buy" rating reaffirmed by analysts at Raymond James Financial, Inc..
12/11
05:42 am
mirm
Low
Mirum Pharmaceuticals (MIRM): Assessing Valuation After Strong Long-Term Returns and Recent Share Price Pullback [Yahoo! Finance]
12/10
07:00 pm
mirm
Low
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12/10
05:04 pm
mirm
Low
Mirum Pharmaceuticals (NASDAQ:MIRM) had its "outperform" rating reaffirmed by analysts at Leerink Partners.
12/10
05:03 pm
mirm
Low
Mirum Pharmaceuticals (NASDAQ:MIRM) was given a new $100.00 price target on by analysts at Leerink Partners.
12/9
09:11 am
mirm
Medium
Mirum Pharmaceuticals (NASDAQ:MIRM) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
12/8
07:00 pm
mirm
Medium
Mirum Pharmaceuticals (NASDAQ:MIRM) was given a new $88.00 price target on by analysts at Robert W. Baird.
12/8
06:07 pm
mirm
Medium
Mirum Pharmaceuticals (NASDAQ:MIRM) had its "outperform" rating reaffirmed by analysts at Evercore ISI.
12/8
11:01 am
mirm
Low
Mirum Pharmaceuticals (NASDAQ:MIRM) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
11/4/2025
04:01 pm
mirm
-1.2%
BEAT
8/6/2025
04:01 pm
mirm
12.0%
BEAT
5/7/2025
04:01 pm
mirm
9.8%
BEAT
Earnings are essential to understanding the financial health of a company listed on any Stock Exchange. But what are Earnings, how are they calculated, when are they announced, and how are they used to make sound investment decisions? The answers are right here.
12/11
09:04 am
Reiterates
Strong-Buy
Strong-Buy
Raymond James Financial, Inc.
Low
0.4%
12/10
05:04 pm
Reiterates
Outperform
Outperform
Leerink Partners
Low
1.6%
12/9
12:17 pm
Maintains
Overweight
Overweight
Morgan Stanley
Low
-1.5%
12/9
12:17 pm
Maintains
Overweight
Overweight
Morgan Stanley
Low
-1.5%
12/9
11:45 am
Maintains
Outperform
Outperform
Baird
Low
-1.6%
12/9
11:45 am
Maintains
Outperform
Outperform
Baird
Low
-1.6%
12/9
10:29 am
Maintains
Outperform
Outperform
Evercore ISI Group
Low
-2.3%
12/9
09:11 am
Reiterates
Overweight
Overweight
Morgan Stanley
Medium
-3.7%
12/9
09:11 am
Reiterates
Overweight
Overweight
Morgan Stanley
Medium
-3.7%
12/8
08:01 am
mirm
Low
Form 8-K Mirum Pharmaceuticals, For: Dec 06
12/5
12:46 pm
mirm
Low
Form SCHEDULE 13G/A Mirum Pharmaceuticals, Filed by: JANUS HENDERSON GROUP PLC
12/2
04:04 pm
mirm
Low
Form 4 Mirum Pharmaceuticals, For: Dec 01 Filed by: GREY MICHAEL G
12/1
04:07 pm
mirm
Low
Form 144 Mirum Pharmaceuticals, Filed by: GREY MICHAEL G
11/25
04:10 pm
mirm
Low
Form 4 Mirum Pharmaceuticals, For: Nov 21 Filed by: GREY MICHAEL G
11/21
04:10 pm
mirm
Low
Form 144 Mirum Pharmaceuticals, Filed by: GREY MICHAEL G
11/20
04:21 pm
mirm
Low
Form 4 Mirum Pharmaceuticals, For: Nov 18 Filed by: Peetz Christopher
11/17
04:52 pm
mirm
Low
Form 8-K Mirum Pharmaceuticals, For: Nov 17
11/14
04:18 pm
mirm
Low
Form SCHEDULE 13G/A Mirum Pharmaceuticals, Filed by: BIOTECHNOLOGY VALUE FUND L P
Show more
Top News Gainers
12/13 Mirum Pharmaceuticals to Provide Regulatory Update in Upcoming Conference Call and Webcast 111.0%
3/23 Form 4 Mirum Pharmaceuticals, For: Mar 19 Filed by: Tucker Edwin Jonathan 20.8%
3/12 Form 10-K Mirum Pharmaceuticals, For: Dec 31 16.2%
1/16 Frazier Healthcare Partners Closes Oversubscribed $617 Million Life Sciences Fund 15.2%
12/7 Mirum Pharmaceuticals (NASDAQ: MIRM) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 11.2%
4/17 Mirum Pharmaceuticals (NASDAQ: MIRM) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 6.0%
4/28 Mirum Pharmaceuticals Appoints Peter Radovich as Chief Operating Officer 5.5%
4/30 Form 3 Mirum Pharmaceuticals, For: Apr 28 Filed by: Radovich Peter 5.4%
2/18 Mirum Pharmaceuticals to Participate at Four Upcoming Conferences 5.0%
4/9 Mirum Pharmaceuticals (NASDAQ: MIRM) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $15.00 price target on the stock. 4.7%
Top News Decliners
3/17 Mirum Pharmaceuticals (MIRM) Investor Presentation - Slideshow [Seeking Alpha] -10.7%
1/8 Mirum Pharmaceuticals Announces Pricing of Public Offering -6.6%
1/6 Form S-1 Mirum Pharmaceuticals, -6.0%
12/17 Mirum Pharmaceuticals (NASDAQ: MIRM) had its price target raised by analysts at Citigroup Inc from $21.00 to $30.00. They now have a "buy" rating on the stock. -5.8%
4/16 Mirum Pharmaceuticals (NASDAQ: MIRM) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $17.00 price target on the stock. -5.6%
1/9 Form 424B4 Mirum Pharmaceuticals, -5.0%
8/28 Mirum Pharmaceuticals Reports Second Quarter Financial Results and Provides Corporate Update -4.8%
8/12 Mirum Pharmaceuticals (NASDAQ: MIRM) is now covered by analysts at Citigroup Inc. They set a "buy" rating on the stock. -4.6%
12/28 Mirum Pharmaceuticals (NASDAQ: MIRM) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -4.4%
9/26 Mirum Pharmaceuticals to Present at Cantor 2019 Global Healthcare Conference -3.9%